Point-of-care PCR shows promise for Babesia gibsoni in Hong Kong dogs

A new study in Veterinary Sciences evaluates whether a point-of-care multiplex PCR analyzer can accurately detect Babesia gibsoni in dogs in Hong Kong, where the parasite is a major clinical concern. The core finding is straightforward: compared with reference laboratory PCR, the in-clinic platform performed well on a retrospective sample set, pointing to a possible faster route to molecular confirmation in cases where every hour can shape treatment and monitoring decisions. (sciencedirect.com)

The backdrop is an unusually relevant one. In Hong Kong, B. gibsoni has been reported as the most common arthropod-borne infection in dogs, and among owned dogs tested for suspected tick-borne disease, Babesia spp. were detected in 28.8% of samples, with B. gibsoni accounting for 408 of 435 Babesia-positive cases in one large dataset from 2018 to 2021. City University of Hong Kong’s veterinary diagnostic laboratory already offers molecular testing for babesiosis, underscoring how established PCR is as the diagnostic standard, even if access and turnaround can still limit immediate decision-making in practice. (sciencedirect.com)

According to the study summary provided, the investigators, See Mun Tsang, Virginia Merino, and Jane Yu, assessed 47 canine EDTA blood samples collected between May 2024 and June 2025, comparing a point-of-care multiplex PCR analyzer against reference laboratory PCR for B. gibsoni detection. While the full article text was not readily accessible in the search results, the study’s premise aligns with a longstanding diagnostic challenge: conventional PCR is highly sensitive, but it generally requires lab infrastructure, batching, and transport, which can delay confirmation. Earlier research in dogs has repeatedly framed that tradeoff as a barrier to timely care, especially when parasitemia is low and blood smear interpretation is difficult. (pmc.ncbi.nlm.nih.gov)

That diagnostic gap is especially important because the clinical picture can be suggestive, but not definitive. In a 2025 Hong Kong case series of 108 PCR-positive dogs, the most common signs included anorexia, pallor, lethargy, pigmenturia, and fever, while moderate to marked thrombocytopenia and anemia were common laboratory findings. Earlier Hong Kong prevalence work also found thrombocytopenia, neutropenia, and pancytopenia were significantly associated with B. gibsoni infection, and advised clinicians to consider testing even when thrombocytopenia appears without anemia. Together, those findings support the case for faster molecular confirmation in dogs with compatible hematologic changes. (scholars.cityu.edu.hk)

Direct outside commentary on this specific paper was limited in the available search results, but the broader expert view is consistent: PCR remains the most reliable method for detecting B. gibsoni, and point-of-care molecular formats are attractive because they can shorten time to diagnosis without relying on microscopy alone. Prior peer-reviewed work on portable or rapid PCR systems for B. gibsoni has reached similar conclusions, describing these platforms as potentially useful for rapid, sensitive, clinic-level detection. That doesn’t prove all systems are interchangeable, but it does suggest this Hong Kong study fits into a growing body of work aimed at bringing molecular parasitology closer to frontline practice. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is less about gadgetry and more about workflow. When B. gibsoni is prevalent in the local canine population, a test that can move PCR-quality detection nearer to the point of care could change how quickly clinicians triage anemia and thrombocytopenia cases, decide on confirmatory testing, counsel pet parents, and initiate treatment or monitoring. In endemic regions, it may also support better antimicrobial stewardship and more targeted use of referral lab resources by helping practices distinguish probable babesiosis from a broader tick-borne differential earlier in the visit. That said, interpretation still depends on prevalence, pretest probability, and the risk of false positives or false negatives in real-world use. (sciencedirect.com)

There are also broader market implications. Hong Kong has an active veterinary molecular diagnostics ecosystem, and startup activity around rapid veterinary nucleic acid testing suggests commercial interest in bringing these tools into private practice. If additional validation confirms strong performance across larger and more diverse canine populations, point-of-care PCR could become a more practical option not just for referral centers, but for general practices managing suspected vector-borne disease. (cityu.edu.hk)

What to watch: The next step is external validation: larger prospective studies, clearer reporting of sensitivity, specificity, predictive values, and operational factors such as turnaround time, staff training, contamination control, and cost per test. For clinicians, the real question is whether these systems can deliver reliable same-visit answers at a price and complexity level that fits everyday practice in endemic settings. (pmc.ncbi.nlm.nih.gov)